Health And Pharma

Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

Clinical Trials

Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer

FDA & EMA

FDA Grants Fast Track Designation to RPTR-1-201 for Advanced Triple- Breast Cancer

ONCOLife

PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer

ONCOLife

Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer

ONCOLife

ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit

Clinical Trials

Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk

ONCOLife

Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer

ONCOLife Issues

Featured Articles

FDA Approves Enhertu for Two New HER2-Positive Early Breast Cancer Indications

The FDA approved Enhertu (trastuzumab deruxtecan) for two HER2-positive early breast cancer indications: neoadjuvant T-DXd followed by THP in Stage II or III disease and adjuvant T-DXd for residual invasive disease after neoadjuvant therapy....

FDA Approves First All-Oral INQOVI Plus Venetoclax Regimen for Newly Diagnosed AML

FDA Approves Sonrotoclax as First BCL2 Inhibitor for R/R Mantle Cell Lymphoma

FDA Approves Bizengri as First Targeted Therapy for NRG1 Fusion+ Cholangiocarcinoma

FDA Grants RMAT Designation to RZ-001, a Novel RNA Therapy for Hepatocellular Carcinoma

FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma

FDA Accepts IBTROZI sNDA After Durable Long-Term Benefit in Advanced ROS1+ Lung Cancer

Trending Articles

Zeta Navigation System Gains FDA Clearance for Brain Tumor Biopsy and Neurosurgery

FDA Approves Vepdegestrant, First PROTAC Therapy for ESR1+ ER+/HER2- Breast Cancer

SUNRISE-II Trial Begins Evaluating Ultrasound-Guided HIFU Ablation for Pancreatic Cancer

Clinical Trials

Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy

OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer

Clinical Trials

AidaBREAST Gains FDA Breakthrough Status for Personalized Radiotherapy in Breast Cancer

Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma

Clinical Trials

Early CAR T-Cell Intervention Shows Disease-Eradication Potential in High-Risk Myeloma

Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer

Clinical Trials

World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer

Clinical Trials

Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC

FDA-Cleared Utepreva Device Aims to Improve Early Endometrial Cancer Detection

PLN-101095 Plus Pembrolizumab Shows Durable Responses in ICI-R Solid Tumors

Opaganib Shows Dual Preclinical Promise in Neuroblastoma and Triple- Breast Cancer

Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer

FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma

FDA & EMA

FDA Gives Priority Review to PADCEV Plus Pembrolizumab in MI Bladder Cancer

FDA & EMA

AACR26 Data Show Multi-Biomarker MCED Approach Improves Early Cancer Detection

ONCOLife

FDA Grants Breakthrough Status to First Urine-Based Multi-Cancer Early Detection Test

ONCOLife

Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer

AI Nodule Detection Helps Sarasota Memorial Reach 75% Early Lung Cancer Diagnosis

AI

Illumina Launch 100 K Genome Effort to Advance Cancer and Rare Disease Research

AI

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

FDA & EMA

Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer

ONCOLife

Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

FDA & EMA

MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer

ONCOLife

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

ONCOLife

New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy

ONCOLife